4-(2',4'-dichlorophenyl)amino-6-nitroquinazoline | 1428063-43-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(2',4'-dichlorophenyl)amino-6-nitroquinazoline
• 英文别名: N-(2,4-dichlorophenyl)-6-nitroquinazolin-4-amine；4-(2,4-dichlorophenylamino)-6-nitroquinazoline
• CAS: 1428063-43-7
• 化学式: C₁₄H₈Cl₂N₄O₂
• 分子量: 335.149
• InChiKey: DVZDULWBSSHZLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2',4'-dichlorophenyl)amino-6-nitroquinazoline 在 ammonium hydroxide 、 sodium dithionite 作用下， 以 乙醇 、 水 为溶剂， 反应 3.5h， 生成 (Z)-ethyl 3-[4-(2,4-dichlorophenylamino)quinazolin-6-ylamino]-2-cyanoacrylate
  参考文献：
  名称：

  Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors

  摘要：

  4-Anilino-6-substituted-quinazolines were designed, synthesized and evaluated for EGFR-TK and tumor growth inhibitory activities. The target compounds were designed with enamine ester or urea moieties appended at the C-6 of quinazoline as additional hydrogen bond acceptor functions. Most of the synthesized compounds displayed potent EGFR-TK inhibitory activity at 10 mu M and the 6-ureido-anilinoquinazoline derivative 7a showed IC50 value of 0.061 mu M. Moreover, six compounds were tested by National Cancer Institute (NCI), USA for their anti-proliferative activity at 10 mu M in full NCI 60 cell panel. Compound 7a was further assayed for five dose molar ranges in full NCI 60 cell panel and exhibited remarkable growth inhibitory activity pattern against Non-Small Cell Lung Cancer EKVX (GI(50) = 037 mu M), NCI-H322M (GI(50) = 0.36 mu M), Renal Cancer A498 (GI(50) = 0.46 mu M), TK-10 (GI(50) = 0.99 mu M) and Breast Cancer MDA-MB-468 (GI(50) = 1.096 mu M) which are of high EGFR expression. Docking study was performed for the active compounds into ATP binding site of EGFR-TK which showed similar binding mode to gefitinib and additional binding with Cys-773 at the gatekeeper of EGFR-TK enzyme. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.10.017
• 作为产物：
  描述：

  2-氰基-4-硝基苯胺 在 溶剂黄146 作用下， 反应 1.5h， 生成 4-(2',4'-dichlorophenyl)amino-6-nitroquinazoline
  参考文献：
  名称：

  4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis

  摘要：

  4-Arylamino-6-nitroquinazolines (2-25) were synthesized and evaluated for their leishmanicidal activities against Leishmania major promastigotes in vitro with IC50 values = 1.87-61.48 mu M. Among the twenty four synthetic derivatives, 4-[4'-(methylsulfanyl)phenyljamino-6-nitroquinazoline (21), and 4-(2'-methoxyphenyl)amino-6-nitroquinazoline (8) showed excellent antileishmanial activities with IC50 values 1.87 +/- 0.31 and 437 +/- 0.02 mu M, respectively, more active than the standard drug, pentamidine (IC50 = 5.09 +/- 0.09 mu M). Compound 16 (IC50 = 6.53 +/- 0.21 mu M) displayed an activity comparable to the standard. Compounds 15 (IC50 = 9.04 +/- 0.03 mu M), 18 (IC50 = 12.28 +/- 0.18 mu M),14 (IC50 = 19.87 +/- 0.22 mu M), and 5 (IC50 = 24.03 +/- 2.71 mu M) also showed good activities. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.11.016

文献信息

• Design, Synthesis and Biological Evaluation of Novel Quinazoline-Based Anti-inflammatory Agents Acting as PDE4B Inhibitors
  作者：Rabah Ahmed Taha Serya、Abeer Hussin Abbas、Nasser Saad Mohamed Ismail、Ahmed Esmat、Dalal Abdelrahman Abou El Ella

  DOI：10.1248/cpb.c14-00737

  日期：——

  A novel series of quinzoline based compounds (IIIa–d, VIa–f, IXa–f) were designed, synthesized and screened for their inhibitory activity towards the PDE4B isoform. The in vivo anti-inflammatory effect of the titled compounds (IIIa–d, VIa–f, IXa–f) as well as their effect on the level of tumor necrosis factor (TNF-α) were evaluated. Among all of the synthesized compounds, IXb, IXd and IXf, exhibited good inhibitory activity against PDE4B enzyme with inhibition percentages of 42, 62 and 68%, respectively. Most of the tested compounds showed potent anti-inflammatory activity compared to indomethacin with a marked decrease in TNF-α level. The ulcerogenic effect of the tested compounds was also examined. The gastric mucosa of the tested animals remained intact after oral administration of the hit compounds. Additionally, docking study was used to explore the possible binding mode of the active compounds on the PDE4B enzyme as well as to illustrate the selectivity of the active hits on the PDE4B isoform.

  设计、合成并筛选了一系列基于喹唑啉的化合物（IIIa–d、VIa–f、IXa–f），以评估它们对PDE4B亚型的抑制活性。评估了目标化合物（IIIa–d、VIa–f、IXa–f）的体内抗炎作用及其对肿瘤坏死因子（TNF-α）水平的影响。在所有合成的化合物中，IXb、IXd和IXf对PDE4B酶表现出良好的抑制活性，抑制百分比分别为42％、62％和68％。与吲哚美辛相比，大多数测试化合物显示出强大的抗炎活性，TNF-α水平显著降低。还检查了测试化合物的致溃疡作用。测试动物在接受命中化合物的口服给药后，胃粘膜保持完整。此外，对接研究用于探索活性化合物在PDE4B酶上的可能结合模式，并说明活性命中对PDE4B亚型的选择性。
• Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors
  作者：Samar Mowafy、Nahla A. Farag、Khaled A.M. Abouzid

  DOI：10.1016/j.ejmech.2012.10.017

  日期：2013.3

  4-Anilino-6-substituted-quinazolines were designed, synthesized and evaluated for EGFR-TK and tumor growth inhibitory activities. The target compounds were designed with enamine ester or urea moieties appended at the C-6 of quinazoline as additional hydrogen bond acceptor functions. Most of the synthesized compounds displayed potent EGFR-TK inhibitory activity at 10 mu M and the 6-ureido-anilinoquinazoline derivative 7a showed IC50 value of 0.061 mu M. Moreover, six compounds were tested by National Cancer Institute (NCI), USA for their anti-proliferative activity at 10 mu M in full NCI 60 cell panel. Compound 7a was further assayed for five dose molar ranges in full NCI 60 cell panel and exhibited remarkable growth inhibitory activity pattern against Non-Small Cell Lung Cancer EKVX (GI(50) = 037 mu M), NCI-H322M (GI(50) = 0.36 mu M), Renal Cancer A498 (GI(50) = 0.46 mu M), TK-10 (GI(50) = 0.99 mu M) and Breast Cancer MDA-MB-468 (GI(50) = 1.096 mu M) which are of high EGFR expression. Docking study was performed for the active compounds into ATP binding site of EGFR-TK which showed similar binding mode to gefitinib and additional binding with Cys-773 at the gatekeeper of EGFR-TK enzyme. (C) 2012 Elsevier Masson SAS. All rights reserved.
• 4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis
  作者：Syed Muhammad Saad、Nida Ghouri、Shahnaz Perveen、Khalid Mohammed Khan、M. Iqbal Choudhary

  DOI：10.1016/j.ejmech.2015.11.016

  日期：2016.1

  4-Arylamino-6-nitroquinazolines (2-25) were synthesized and evaluated for their leishmanicidal activities against Leishmania major promastigotes in vitro with IC50 values = 1.87-61.48 mu M. Among the twenty four synthetic derivatives, 4-[4'-(methylsulfanyl)phenyljamino-6-nitroquinazoline (21), and 4-(2'-methoxyphenyl)amino-6-nitroquinazoline (8) showed excellent antileishmanial activities with IC50 values 1.87 +/- 0.31 and 437 +/- 0.02 mu M, respectively, more active than the standard drug, pentamidine (IC50 = 5.09 +/- 0.09 mu M). Compound 16 (IC50 = 6.53 +/- 0.21 mu M) displayed an activity comparable to the standard. Compounds 15 (IC50 = 9.04 +/- 0.03 mu M), 18 (IC50 = 12.28 +/- 0.18 mu M),14 (IC50 = 19.87 +/- 0.22 mu M), and 5 (IC50 = 24.03 +/- 2.71 mu M) also showed good activities. (C) 2015 Elsevier Masson SAS. All rights reserved.